The NMIBC market is gaining momentum, with ~13 therapies anticipated to enter key markets by 2034. DelveInsight projects that three critical drugs will secure billion-dollar markets across the 7MM by 2034, highlighting the significant potential in the NMIBC space. This growth is driven by the demand for new treatment options, the high treatment costs, the focus on various patient segments, and the increasing prevalence of NMIBC.
LAS VEGAS , Sept. 23, 2024 /PRNewswire/ -- Non-muscle-invasive bladder cancer (NMIBC) is a type of bladder cancer where the tumor remains confined to the bladder's innermost lining layer, without spreading into the muscle. This early-stage form constitutes a large portion of bladder cancer cases.
NMIBC usually features superficial tumor growth and is commonly associated with papillary tumors or carcinoma in situ . Based on DelveInsight's assessment in 2023, the total prevalent cases of NMIBC in the 7MM were nearly 1.5 million .
These cases are expected to increase by 2034. Among cases categorized by risk level, the highest number belonged to the intermediate-risk category . The current treatment plan involves surgery , intravesical immunotherapy (BCG) , and intravesical chemotherapy .
For intermediate- or high-risk NMIBC, the standard approach typically includes Transurethral Resection of Bladder Tumor (TURBT) followed by adjuvant BCG immunotherapy, which is considered the gold standard for reducing tumor recurrence and preventing progression to more .
